Effect of Weight Loss Induced by Intragastric Balloon Therapy on Cardiac Function in Morbidly Obese Individuals: A Pilot Study

Abstract

Objective: The aim of the study was to investigate the effect of intragastric balloon therapy on left ventricular function and left ventricular mass in a cohort of morbidly obese patients. Subjects and Methods: A prospective trial was performed in a cohort of 17 class II and class III morbidly obese individuals. The intragastric balloon was retained in the stomach for an average of 6 months. Conventional and tissue Doppler echocardiography were performed in all patients before and after the procedure. Results: The mean age of the study participants was 36 ± 10 years (range: 18-55). The mean body mass index was significantly decreased following the intragastric balloon insertion procedure (44 ± 8 vs. 38 ± 5, p < 0.001). The left ventricular mass index and left atrial volume index were significantly decreased following the procedure (112 ± 21 vs. 93 ± 17, p = 0.001 and 20 ± 6 vs. 14 ± 5, p = 0.02, respectfully). In addition, the ratio of mitral peak early diastolic velocity to tissue Doppler-derived peak diastolic velocity and tissue Doppler echocardiography-derived left ventricular myocardial performance index were decreased significantly following the procedure (9.5 ± 1.9 vs. 7.7 ± 1.5, p = 0.002 and 0.57 ± 0.11 vs. 0.46 ± 0.06, p = 0.001, respectively). Conclusions: Intragastric balloon therapy resulted in significant weight reduction in morbidly obese patients. This weight reduction was associated with improved left ventricular function.

Low prevalence of obesity in Behçet’s disease is associated with high obestatin level

“…It has been reported that weight loss ameliorates several metabolic complications associated with atherosclerotic diseases and improves cardiac functions (30,31). Similarly, decreased ghrelin levels are associated with a variety of metabolic abnormalities and atherosclerotic cardiovascular diseases (32).…”

Nonalcoholic fatty liver disease: implications for cardiovascular risk

“…There is increasing interest in the use of endoscopic bariatric therapies beyond its primary objective of achieving weight loss, resolving MetS, and NASH. A small prospective pilot study assessed the effect of intragastric balloon therapy on left ventricular (LV) function and LV mass in morbidly obese patients at 6 months [106]. BMI, LV mass index, and left volume index were significantly decreased (44 8 vs. 38 5, P < 0.001, 112 21 vs. 93 17, P = 0.001, and 20 6 vs. 14 5, P = 0.02, respectively) following intragastric balloon placement.…”